RxDoctor Payments Data

Uday Ranjit, MD

Nephrology · Orlando, FLNPI 1851384994

Payments from drug & device makers

$4,081in general payments, 2019–2025

Across 197 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$525
  • Calliditas Therapeutics US Inc.$494
  • Vifor Pharma, Inc.$454
  • Amgen$395
  • Aurinia Pharma U.S., Inc.$280
  • Mallinckrodt Hospital Products Inc.$239
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$3,94497%
  • Education$1373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,081 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$240,581
Medicare patients
411
Services billed
4,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NulojixBelatacept19$53,966
Valganciclovir Hcl89$22,380
VeltassaPatiromer Calcium Sorbitex20$19,978
EliquisApixaban19$14,773
Cinacalcet Hcl32$12,461
Tacrolimus47$10,498
MultaqDronedarone Hcl12$8,469
Leflunomide86$7,696
Janumet XrSitagliptin Phos/Metformin Hcl12$6,976
CreonLipase/Protease/Amylase17$5,290
Mycophenolic AcidMycophenolate Sodium22$4,786
Testosterone11$3,071
Dexlansoprazole DrDexlansoprazole15$2,699
Calcium Acetate38$2,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Nulojix$33$53,96619 claims
MerckJanumet Xr$46$6,97612 claims
AbbVieCreon$20$5,29017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →